small positions in ten of these biotechs, say nine of them go to zero, as long as the tenth was regeneronu still would have made a massive gain the risk-reward of trying to find these speculative winners makes sense when you're young. for older investors, speculation is a much more risky gain and i only recommend playing with excess cash that you can afford to lose. here's the bottom line, remember to speculate while you're still young enough to take the hit if something goes wrong as long as you're disciplined and only make a small part of your discretionary portfolio, it's absolutely worth hunting for the next regeneron without hesitation much more "mad money" ahead. i've got the answer to the question, stocks or bonds? the able-old wisdom you've heard is wrong and i'm about to rewrite the script and the game plan you need to follow when the bear market strikes. and it's the most important piece of advice about financial health many of you will have to take action tomorrow. don't miss this. stick with cramer. >>> what's better than "mad money" how about more "mad money. follow "mad mone

regeneron, this is on an analyst, the company might give back a good portion of its more than 30% gain since the end of april. that is where we saw initial prescription data for its drug which treats dermatitis. bayer said those expectations are now too high, and is downgrading it to underperform from neutral. those shares off by 4%. mark: julie hyman, thank you for that. vonnie: equity bearers are hunting for excess in the stock market and might be better off worrying about bond prices according to alan greenspan, the former fed chair who says that's where the bubble is and if it pops it will be real bad for everyone. are real treasury yields hitting far below where they should be? joining us is bloomberg's intelligence senior u.s. economist and stocks reporter oliver renick. aal yields have inched up little faster in the last day or two then we might have been anticipating given how they happen moving, but still sluggish. >> still very low by historical standards, absolutely. will we search? probably not. ,e heard from the fed chair stanley fischer delivered an excellent speech on re

. >>> we're back shares of regeneron trading higher after a big earnings beat and raising its full-yearuidance up 28% strong sales of its drug to treat macular degeneration. >> what's next in the pipeline for regeneron? joining us is the president and co-founder you're chief scientific officer and principaland developer of six fda-approved drugs let me ask you something out of left field we just heard that martin shkreli is a quote unquote genius and talent who need to be in the pharmaceutical industry to develop treatments. would you agree with that characterization >> honestly i don't think about shkreli that much. i don't know him at all but i know we're really in a very different business we're not in the business of buying old drugs and then repricing them and trying to make a profit. as you were just saying, we're in the business of coming up with brand new discoveries and coming out with important new treatments for patients and being really innovative so all of our drugs are discovered by our people in our labs, and they are all, we think, representing important breakthroughs fo

jpmorgan went from upgrade from neutral shares down after a weak earnings report but today up 4.5% and regeneron was cut on expectations that the company may be too high for treatment for adults with moderate to severe eczema. that stock down 2.6%. >> facebook recently shut down a program where bots started communicating in their own language julia boorstin has the details how scared of this should we be, julia? don't be scared facebook did shut down an experimental ai program but not because they were concerned about robots taking over the world. facebook has been training bots to negotiate with each other to help people them to messenger users. when they realized they made a mistake by failing to get them to communicate in english but rather than our shorthand they shut the program down. bots are increasingly important to facebook, they bought oslo to give recipes and recommend restaurants and movie showtimes and other thing. they will integrate the oslo team to help ramp uppies messenger tools. bots are key for facebook to try to make more money off of facebook it's a top priority. if the bot

but regeneron beat estimates by a full dollar.ong sales of its flagship eye drug and that stock is up by 3.8%. >>> the bank of england has left its key interest rates unchanged. the bank also trimming its growth forecast for this year and next year citing the impact of the impending brexit. >>> wyndham worldwide is splitting into two separate companies. one of those companies will involve the hotel business the other will be running the time-sharing unit. that's similar to moves made by competitors like marriott and hilton recently. the company expects the split to be completed during the first half of 2018 the stock is up by 6.7%. >> okay. >>> let's talk now and get all the answers here the white house says that overhauling the nation's infrastructure is still a priority for president trump what does that mean, still a priority why, what happened but if negotiations on tax reform, the budget and the debt ceiling eat up time, it could be while before we see movement on what our next guest says it is a winning issue. joining us now